Clinical trial ORIENT-15
A Multicenter, Double-blind, Randomised Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-line Treatment of Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Cancers | |
---|---|
Organ | Esophagus |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Innovent Biologics (Suzhou) Co., Ltd. |
EudraCT Identifier | 2020-000533-40 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03748134 |
Last update |